Skip to content

Theravance Biopharma TBPH Ratios & Valuation

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
Profitability
Operating margin1.2%+78.1pp-3.4%+69.6pp-40.9%+28.8pp-48.2%+19.4pp-76.9%-8.1pp
Net margin104.3%+194pp98.5%+186pp36.5%+115pp16.9%+90.5pp-89.4%-16.6pp
Returns
Return on equity50.2%+81.6pp44.8%+73.9pp14%+36.9pp6.2%+25.5pp-31.5%
Efficiency
Asset turnover0.3×+0.1×0.3×+0.1×0.2×0.0×0.2×0.0×0.2×0.0×
Liquidity
Current ratio13.1×+8.4×10.9×+5.9×9.5×+4.5×6.7×+1.5×4.8×-1.0×
Leverage
Debt-to-equity0.1×-0.2×0.1×-0.1×0.2×-0.1×0.2×0.0×0.3×+0.1×
Per Share
Book value per share$5.67+69.7%$5.76+60.3%$4.48+18.4%$4.43+11.6%$3.34-21.3%
Valuation
Market capitalization$890.32M+67.5%$948.08M+105%$735.27M+87.1%$533.51M+30.3%$441.77M-0.3%
Price / earnings7.8×
Price / sales8.1×0.0×8.8×+1.6×9.2×+2.9×6.9×+0.3×6.8×-0.4×
Price / book3.1×-0.1×3.2×+0.6×3.2×+1.0×2.4×+0.3×2.7×+0.5×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Theravance Biopharma's profit margins?
Theravance Biopharma (TBPH) runs a 60.8% gross margin and a 1.2% operating margin, with a 104.3% net margin.
Where do Theravance Biopharma's ratios come from?
Every ratio is computed from Theravance Biopharma's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.